Share Prices & Company Research

Market News

21 Jan 2021 | 13:53

Evgen reports 'highly positive' data from SFX-01 trial

(Sharecast News) - Clinical-stage drug development company Evgen Pharma announced on Thursday that its collaboration with a prominent European university had generated "highly positive" data for 'SFX-01' in pre-clinical models of glioma and glioblastoma. The AIM-traded firm said glioma is the most common form of brain tumour affecting around five people in every 100,000.

It said the more severe grade IV classification, glioblastoma, is a "very serious" form of brain tumour representing 45% of all cases, with a poor prognosis and median survival of around 14 months.

The five-year survival of the severe grades was 5%.

Evgen said the data generated for SFX-01 in standard pre-clinical models and orthotopic models, where glioma cells were implanted in brain tissue representing a more disease-relevant model, showed tumour shrinkage and "significantly extended" survival times.

SFX-01 was also found to potentiate, or substantially increase, the therapeutic effect of radiotherapy in these models.

The therapeutic options for glioma were limited to surgery, radiotherapy and one widely-available drug, temozolomide.

There was a "clear unmet need" for more treatments for use in conjunction with the current standard of care, the company explained.

"We are excited by this compelling new data in a type of cancer which has severely limited therapeutic options for the patient," said chief executive officer Dr Huw Jones.

"The positive tolerability profile of SFX-01 makes it a viable option for use in addition to current treatments.

"Our plan is to expand upon these preclinical data in this and new collaborations, and start the process of designing an appropriate phase 2 clinical trial."

At 1157 GMT, shares in Evgen Pharma were up 4.72% at 11.1p.
Get in touch today
Join Redmayne Bentley
Talk to us now about opening a new account or transferring your account from another provider
0113 243 6941
Get in touch today
Contact your local office
Contact your local office to find out more
The value of your investments and the income from them may go down as well as up, and you could get back less than you invested.
Continuing our Personal Service: View our Latest COVID-19 Update: 30th April 2021
We use cookies on this site to improve your experience and help us provide you with a better website. An explanation of the cookies we use and their purpose can be found within our Cookie Policy. Your continued use of this site means you consent to the use of cookies.